Previous Close | 12.74 |
Open | 12.56 |
Bid | 11.89 x 0 |
Ask | 11.90 x 0 |
Day's Range | 11.76 - 12.56 |
52 Week Range | 10.12 - 39.11 |
Volume | |
Avg. Volume | 759,075 |
Market Cap | 4.302B |
Beta (5Y Monthly) | 1.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.45 |
Earnings Date | Aug 01, 2022 - Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 10, 2010 |
1y Target Est | 43.68 |
ASX, CNMD, and BHC have been added to the Zacks Rank #5 (Strong Sell) List on May 19, 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride
TFSA investors should look to snatch up undervalued TSX stocks like Manulife Financial (TSX:MFC)(NYSE:MFC) in the middle of spring. The post Canadians: Now Is a Great Time to Snag These TSX Stocks for Your TFSA! appeared first on The Motley Fool Canada.